The Belgian drugmaker will use Accenture's INTIENT Pharmacovigilance to monitor the safety of its drugs, including those that are on the market and in clinical trials. Germany's Bayer inked a similar deal with Genpact last year.
Results of the BE VIVID study showed that UCB's bimekizumab showed a statistically significant improvement in skin clearance compared with J&J's Stelara and placebo.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Brussels-based drugmaker said the acquisition of Ra would boost its potential for leadership in the autoimmune disease myasthenia gravis, as both companies have drugs in Phase III development for it.
The agreement would have allowed UK pharmaceutical regulations to remain under EMA authority after Brexit. Uncertainty around the planned withdrawal has caused worry in the life sciences sector.
LindaCare is a health IT startup developing remote monitoring tools aimed at minimizing alert fatigue for hospitals.
BRUSSELS (Reuters) – Belgian medical researchers have succeeded in repairing bones using stem cells from fatty tissue, with a new technique they believe could become a benchmark for treating a range of bone disorders. The team at the Saint Luc university clinic hospital in Brussels have treated 11 patients, eight of them children, with fractures […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.